ClinicalTrials.gg
CompletedNCT06557356Updated Jan 20, 2026

A Study of LY3532226 in Participants With Obesity

A Phase 1 interventional study of LY3532226 and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
84th of 117
132 · median 267
Started
2024
with 19 others
Phase 1
40 of 118
9 open now
Registered
53rd of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 84th largest by enrollment of the 117 interventional ones that give a count, is one of 20 that started in 2024, is one of 40 in phase 1, and was the 53rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²)
  • Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screening and enrollment

Exclusion criteria

Exclusion Criteria:

  • Have a lifetime history of a suicide attempt
  • Have a history or presence of psychiatric disorders, including a history of major depressive disorder within the last 2 years
  • Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire
  • Have a known gastric emptying abnormality, have undergone gastric bypass surgery or restrictive bariatric surgery
  • Have taken approved or medication for weight loss, within the previous 3 months or 5 half-lives of study screening, whichever is earlier
  • Intend to use any weight-loss medications during study participation
  • Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    LY3532226 (Part A)

    LY3532226 administered subcutaneously (SC)

    Drug: LY3532226

  • Placebo comparator
    Placebo (Part A)

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY3532226 (Part B)

    LY3532226 administered SC

    Drug: LY3532226

  • Placebo comparator
    Placebo (Part B)

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY3532226 (Part C)

    LY3532226 administered SC

    Drug: LY3532226

  • Placebo comparator
    Placebo (Part C)

    Placebo administered SC

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to Study Completion (Up to 16 Weeks)

  2. Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to Study Completion (Up to 20 Weeks)

  3. Part C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to Study Completion (Up to 8 Weeks)]

Secondary outcomes

  1. Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3532226

    PK: Cmax of LY3532226

    Time frame: Predose on Day 1 through Week 16

  2. Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3532226

    PK: AUC of LY3532226

    Time frame: Predose on Day 1 through Week 16

  3. Part B: PK: Cmax of LY3532226

    PK: Cmax of LY3532226

    Time frame: Predose on Day 1 through Week 20

  4. Part B: PK: AUC of LY3532226

    PK: AUC of LY3532226

    Time frame: Predose on Day 1 through Week 20

  5. Part C: Pharmacodynamic (PD): Change in insulin sensitivity index (Si)

    Part C: PD: Change in Si

    Time frame: Baseline up to Approximately Week 4

07

Study locations

4 sites
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Dec 2025, 15 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
Aug 16, 2024
Primary completionActual
Dec 12, 2025
CompletionActual
Dec 12, 2025
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06557356
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Aug 16, 2024
Primary completion
Dec 12, 2025
Completion
Dec 12, 2025
Last update
Jan 20, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Macupatide

Start the discussion